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Abstract                                                                                                     
 
Background 
Limited highly active antiretroviral therapy (HAART) in resource-constrained countries 
makes the optimisation of first-line HAART regimens critical in order to improve treatment 
efficacy and overall prognosis. Relevant data from resource-constrained settings is still 
limited. HAART has been available in Botswana since 2002, providing a unique opportunity 
to evaluate the rate of, the reasons for and the factors associated with first-line HAART 
modification. 
Method 
This retrospective survey was undertaken at the Princess Marina Hospital Infectious Disease 
Care Clinic, Botswana. The researcher examined the medical records of all patients who had 
been initiated on first-line HAART between 1 January 2012 and 1 January 2014. This was 
done to determine the rate of, the reasons for and the factors associated with first-line 
HAART modification.  
Results 
Of the 199 patients who met the inclusion criteria and had been initiated on first-line 
HAART, 48 patients (24% –36 female and 12 male) had undergone regimen modification 
over a median follow-up period of 6.9 months ( interquartile range 2.1-19.7 months). Drug 
toxicity accounted for 52% of modifications, 16.8% of patients defaulted, 16.8% had 
virological failure and 14.6% had their HAART modified due to other reasons. Patients with 
abnormal liver function tests at initiation of HAART were more likely to have their HAART 
modified (p = 0.010). Pregnant women on triple antiretroviral prophylaxis were also more 
likely to have their HAART modified (p = 0.054). 
Conclusion 
There was a lower rate of HAART modification compared to previous studies, mainly 
attributable to drug side effects or drug toxicity. Evaluating patients with abnormal liver 
function tests prior to HAART initiation may reduce the modification rate. This would then 
improve drug tolerability while preserving future drug options. 
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1. INTRODUCTION 
Human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) is one 
of the most prevalent and important chronic diseases of our time. Since the beginning of the 
HIV/AIDS pandemic, more than 70 million people have been infected with the HIV virus and 
35 million people have died of HIV/AIDS worldwide.[1] By the end of 2015, a total of 36.7 
million people were estimated to be living with HIV/AIDS globally.[1] Sub-Saharan Africa is 
one of the most severely affected areas, accounting for about 70% of people living with 
HIV/AIDS worldwide.[1]  
In recent years, significant progress has been made in the treatment of HIV, at least partly due 
to the availability of highly active antiretroviral therapy (HAART).[2] The goal of the current 
treatment strategies includes hindering the viral replication as completely as possible through 
a combination of three or more HAART drugs.[3] HAART use has resulted in a significant 
reduction in mortality and morbidity associated with HIV/AIDS worldwide.[2] New global 
efforts have led to a tremendous increase in antiretroviral therapy access, especially in 
resource-constrained countries.[4] In 2016 it was estimated that 19.5 million people living 
with HIV/AIDS globally had access to treatment, reflecting about 53% HAART coverage.[4]  
Even though the challenge of complete coverage still stands in most developing countries, it 
is important that we sustain the benefits of HAART. The long-term success of treatment 
programmes depends on establishing the rate of, the reasons for and the factors associated 
with modification of first-line HAART.[5] Evidence shows that globally up to 70% of 
patients have their HAART modified and that more than 40% of them have it modified in the 
first 12 months of treatment.[5, 6, 7, 8] The main reason for modification or discontinuation 
of HAART is drug toxicity.[9] Drug toxicity may lead to discontinuation or suboptimal 
therapy due to poor adherence and eventually treatment failure. Although this is a global 
problem, affluent countries suffer less because of the variety of treatment options 
available.[10]  
In resource-constrained countries, treatment regimens are limited and fewer options are 
available for patients unable to tolerate HAART. Treatment modification may pose a 
challenge to treatment programmes, impacting on the overall cost of antiretroviral therapy 
and ultimately on patient prognosis.[11] For this reason, it is important to increase the 
duration of a patient’s initial first-line regimen and to optimise the use of well-tolerated 
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drugs.[12] There is thus a need to develop new strategies to maximise drug tolerability and 
treatment benefits from available first-line HAART. In order to achieve this goal, it is 
important to understand the reasons for modifying first-line HAART. This knowledge could 
help to individualise drug regimens that are better tolerated whilst at the same time preserving 
future treatment options. 
Botswana is one of the countries with the highest prevalence of HIV/AIDS in the world with 
350 000 people infected with HIV in 2015.[1] Botswana was one of the first African 
countries to establish a national HIV/AIDS treatment programme called ‘Masa’, meaning 
‘new dawn’ in the Setswana language.[13] Since the introduction of Masa in 2002, the 
national HAART guidelines have been adapted to align with an improved understanding of 
the biology of HIV, to decrease adverse events associated with HAART and to accommodate 
the availability of improved drugs.[13] Currently, more than 78% of people living with 
HIV/AIDS in Botswana have accessed HAART via various clinics and hospitals. As a result, 
Botswana is in a unique position to evaluate the rate of, the reasons for and the factors 
associated with first-line HAART modification in the context of a developing country. 
 Even though studies have been carried out to assess the rate of, the reasons for and the 
factors associated with HAART modification, HAART guidelines have changed over time 
with the use of newer antiretroviral drugs. Most studies were carried out during a time when 
older antiretroviral drugs were in use. Since the introduction of newer HAART drugs with 
improved efficacy and tolerability profiles, there have been limited studies investigating the 
rate of, the reasons for and the factors associated with HAART modification. To improve 
tolerance of first-line HAART, it is therefore important that we continue to investigate the 
rate of, the reasons for and the factors associated with HAART modification with these newer 
improved drugs. 
The author is unaware of any published study in Botswana that assessed the durability of 
first-line HAART. This study could provide information that could help to improve decision 
making concerning newer improved drugs and HAART initiation in HAART-naive patients 
in Botswana. 
2. AIMS AND OBJECTIVES 
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The overall aim of the study was to determine the rate of, the reasons for and the factors 
associated with first-line HAART modification in HAART-naive patients at Princess Marina 
Hospital (PMH) in Gaborone, Botswana. The specific objectives were the following: 
 To determine the rate of first-line HAART modification. 
 To determine the reasons for first-line HAART modification. 
 To identify the factors associated with HAART modification. 
3. METHODS 
3.1 Study design 
This was a retrospective survey, using a standardised data collection checklist to extract data 
from the existing medical records. The researcher decided to adapt a validated checklist that 
had been used in a previous international study.[14] The checklist was modified to include 
patients’ comorbidities and laboratory findings to identify risk factors associated with 
treatment modification. The checklist is available in addendum of this thesis. A pilot test was 
done with five patient files to test the logistics and to gather information prior to the study in 
order to improve the quality and efficiency of the checklist. 
3.2 Study population and patient selection  
All the medical records of HIV-infected patients who attended PMH from 1 January 2012 
to 1 January 2014 were reviewed by the principal researcher to identify those patients 
who met the study inclusion criteria as stated below.  
Inclusion criteria 
1. HIV-positive HAART-naive adults > 15 years, including pregnant women for prevention 
of mother-to-child transmission, who had been initiated on first-line HAART between 1 
January 2012 and 1 January 2014 with cluster of differentiation 4 (CD4) < 350 or World 
Health Organization (WHO) clinical stages 3 or 4. 
2. At least two recorded follow-up visits post HAART initiation. 
3. Initiated on first-line HAART regimens of 
  tenofovir disoproxil (TDF) + emtricitabine (FTC) +  efavirenz (EFV); or  
 TDF + FTC + lopinavir/ritonavir (LPV/r)/ nevirapine (NVP); or  
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  zidovudine (AZT) +  lamivudine (3TC) + EFV/NVP/LPV/r; or  
  abacavir (ABC) + 3TC + EFV/NVP/LPV/r. 
4. Reasons for and dates of treatment modifications available in the records. 
3.3 Setting 
This retrospective survey was carried out at PMH, which has the largest infectious disease 
control outpatient clinic in Botswana. This clinic is run by three medical officers, nine nurses 
and three health care auxiliaries from Monday to Friday. Around 90-100 patients per day and 
more than 13 000 patients annually are seen in this clinic. The hospital also receives 
complicated HIV-related cases from surrounding local clinics to be seen by an HIV specialist 
who runs the clinic on Wednesdays. The hospital is located in the southern part of the 
country. Since 2002, when the Masa HIV/AIDS programme was introduced, the hospital has 
been providing comprehensive HIV care at no charge to the patient as part of the national 
HAART programme.  
In this facility, standard WHO-adapted treatment and care guidelines are followed. During 
the study period, the 2012 Botswana HAART guidelines, which are in accordance with the 
2010 WHO recommendations, were in use. Treatment consisted of nucleotide reverse 
transcriptase inhibitors (NRTI) backbone of TDF or AZT or ABC with FTC or 3TC and 
either NVP, EFV or LPV/r.[15,16] Patients presenting with WHO stages 3 or 4 and/or 
CD4 < 350 cells/mm3 were eligible for the initiation of HAART.[15, 16] Clinical and 
laboratory findings were collected at each hospital visit. 
HAART eligibility for HIV-infected pregnant women was the same as for other adults. All 
pregnant women not eligible for HAART were started on triple antiretroviral therapy (TAP). 
Initiation of TAP depended on the gestational age of the woman. If TAP was given before 14 
weeks of pregnancy, it consisted of TDF + FTC and NVP or LPV/r, depending on the CD4 
count.[15] When given at 14 weeks and more, it was in the form of TDF + FTC + EFV.[16] 
This was because before 14 weeks gestation, EFV was considered teratogenic. The duration 
of TAP postpartum depended on whether the woman was breastfeeding or not. During the 
postpartum period women were assessed for WHO stages 3 or 4, CD4 count and pregnancy 
and postpartum related complications before TAP could be stopped. [15] If women had 
developed WHO stages 3 or 4 or their CD4 count was less than 350, or clinically unstable 
treatment was continued.[16] Post delivery, those who were on NVP were continued on it, 
but those on LPV/r were switched to EFV. It is also important to note that a postpartum 
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woman had an option of continuing HAART even if assessed to have no WHO stages 3 or 4 
disease and/or CD4 > 350, but that option had to be discussed with the medical officer. 
3.4 Measurements and data collection  
For the purpose of this study, modification of HAART was viewed as regimen switch or drug 
substitution in first-line HAART. Dose modifications were not accounted for. Time zero was 
the day of HAART initiation, and the cut-off date was the earliest of regimen modification. 
The reasons for modification were those determined by the physician or medical officer at the 
date of regimen change. The reasons for modification were not assigned prospectively at the 
time of treatment modification. These reasons were grouped retrospectively as drug toxicity, 
virological failure, default and other. 
Laboratory findings were classified as abnormal liver function tests (LFTs), abnormal 
haemoglobin (Hb) and abnormal renal function tests (RFTs). Abnormal RFTs were defined 
as creatinine clearance < 60 cc/minute. Abnormal Hb was below 12.0 g/dL for women and 
below 14.0g/dL for men. Abnormal LFTs were defined as aspartate aminotransferase above 
40 U/L and alanine aminotransferase above 56 U/L. 
The main sources of data collection were the patient’s medical records, the patient’s 
pharmacy refill book and Meditech. Meditech is electronic patient management software used 
in PMH to capture patients’ sociodemographic and clinical information during their hospital 
visits. Pharmacy refill books are used by pharmacists to record any information concerning 
HAART drug prescriptions during hospital visits. Information on any modification of drugs 
is also recorded in these books. 
All the medical records of patients initiated on first-line HAART during the period of 1 
January 2012 to 1 January 2014 were examined by the principal investigator to identify those 
meeting the inclusion criteria. A standardised validated checklist was used to capture 
sociodemographic information, clinical parameters and the reasons for HAART modification. 
From the assessed medical records, 199 patients were found to meet the inclusion criteria for 
the study. Sociodemographic information collected included age and gender while clinical 
parameters included baseline CD4 count, baseline weight, comorbidities, initial regimen, 
clinical stage, LFTs, RFTs and Hb levels. The medical records contained most demographic 
and clinical variables for each visit, hence most patient observations were extracted from this 
source. The reasons for modification of HAART were also extracted from the medical 
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records. Information missing from this source was checked by the principal investigator from 
Meditech and the pharmacy refill books. 
 Information from all the sources was de-identified, entered into a checklist and then entered 
into a Microsoft Excel spreadsheet on a computer. The Excel spreadsheet had variables 
presented in columns and patient study identity in rows. Data was transcribed after collection 
and verified using Excel before being transferred to a Stellenbosch University statistician for 
exportation into STATA version 11 for analysis. 
3.5 Data analysis 
Statistical analysis was done with the help of a statistician at Stellenbosch University. Patient 
demographics and clinical indices at the initiation of treatment were described using 
percentages for categorical data and median and interquartile ranges (IQRs) for continuous 
data. Identified reasons for modification of HAART were also described using percentages. 
Comparison of demographic and clinical characteristics at initiation of HAART was 
performed using chi-square tests, unpaired T-tests or the Kruskall Wallis test.  
Risk factor variables assessed included gender, age, baseline weight, CD4 counts, WHO 
stages, comorbidities, Hb levels, LFTs and RFTs at initiation. Variables significant at 
univariate analysis (p =0.30) were included in the multivariate models. Person year analysis 
was used to determine the rate of HAART modification while time was measured from the 
start of HAART to the earliest regimen modification. 
4. ETHICS STATEMENT 
This study was approved by the ethics committees of the Botswana Ministry of Health, PMH 
(reference number: PMH 5/79 233-2-2016) and Stellenbosch University (reference number: 
S15 /07/139). 
5. RESULTS  
Among the 219 patients who had been initiated on first-line HAART between 1 January 2012 
and 1 January 2014, 12 were excluded from the study because they had been initiated on 
HAART and followed once and then transferred out to local clinics. Five medical records 
were missing from the department while three more patients were excluded because they 
lacked relevant information (demographic and clinical). This left the researcher with 199 
participants meeting the inclusion criteria. During this study, the researcher had access to all 
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medical records, including those of patients lost for follow-up, records of demised patients 
and records of patients who had been transferred out.  
The sample included 199 participants of which 68.8% were female and 31.2% were male. At 
HAART initiation, the median patient age was 36 years (IQR 30-41), the median CD4 count 
was 187 (IQR 92-300) and the median weight was 61 kg (IQR 52-75); 55.8% of the patients 
had started HAART at WHO stages 3 or 4. The majority of patients (90.5%) had been 
initiated on TDF + FTC + EFV as their first-line regimen. 
Of these 199 participants, 9.6% had cancer, 15.6% had tuberculosis (TB), 27.1% had 
anaemia, 9.6% were on TAP because of pregnancy and 24.6% had other comorbidities at the 
initiation of HAART. Also, 4% had abnormal LFTs, 5% had abnormal RFTs and 27.1% had 
abnormal Hb levels (see Table 1 below). 
Table 1: Baseline characteristics of participants 
Characteristics at HAART initiation Median (IQR) 
Age (years) 36 (30-41) 
Baseline CD4 count (cells/mm3) 187 (92-300) 
Baseline weight (kg) 61 (52.9-75) 
 
Gender N (%) 
Male 
Female 
62 (31.2) 
137 (68.8) 
WHO stage N (%) 
WHO stage 1/2 88 (44.2) 
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WHO stage 3/4 111 (55.8) 
Comorbidities and risk groups N (%) 
Cancer 19 (9.6) 
Anaemia 54 (27.1) 
TB 31 (15.6) 
Pregnancy 19 (9.6) 
Other 49 (24.6) 
Laboratory findings at initiation N (%) 
Abnormal LFT 8 (4) 
Abnormal RFT 10 (5) 
Abnormal Hb 54 (27.1) 
First-line HAART regimen N (%) 
TDF + FTC + EFV 
TDF + FTC + NVP 
TDF + FTC + LPV/r 
AZT + 3TC + EFV 
AZT + 3TC + NVP 
ABC + 3TC + EFV 
180 (90.5) 
1 (0.5) 
1 (0.5) 
8 (4.0) 
1 (0.5) 
8 (4.0) 
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EFV = efavirenz, NVP = nevirapine, ABC = abacavir, 3TC = lamivudine, TDF = tenofovir 
disoproxil, FTC = emtricitabine, AZT = zidovudine, TB = tuberculosis, LPV/r = 
lopinavir/ritonavir, TAP = triple antiretroviral prophylaxis, Hb = haemoglobin, LFT = liver 
function test, RFT = renal function test, IQR = interquartile range, kg = kilogram 
Reasons for highly active antiretroviral therapy modification  
Over a median follow-up period of 6.9 months (IQR 2.1-19.7 months), 24% (n = 48) of the 199 
patients had their first-line antiretroviral regimen modified. This represented an overall 
modification rate of 0.09 per 100 person years (confidence interval [CI]: 0.06-0.11) over a total 
of 47 person years follow-up. Table 2 shows the different reasons for treatment modification.  
Table 2: Reasons for HAART modification among participants 
Reasons for HAART modification Frequency 
1. Drug toxicity/drug side effect N (%) 
 
                  EFV-induced rash 
EFV-induced neuropsychiatric toxicity 
TD4-induced renal impairment 
ABC-induced rash 
Lipodystrophy 
AZT-induced anaemia 
LPV/r-induced persistent diarrhoea 
 
                               7 (14.6) 
3 (6.3) 
9 (18.8) 
1 (2.1) 
2 (4.2) 
2 (4.2) 
1 (2.1) 
2. Virological failure 
8 (16.8) 
3. Default 
8 (16.8) 
4. Other 
 
Post TAP 
Poor compliance 
4 (8.3) 
2 (4.2) 
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Resolved renal failure 
 
1 (2.1) 
Total 
48 (100) 
EFV = efavirenz, ABC = abacavir, AZT = zidovudine, LPV/r = lopinavir/ritonavir, TAP = 
triple antiretroviral prophylaxis, TDF = tenofovir disoproxil 
Table 2 shows that 52.3% of treatment modifications were due to drug side effects or drug 
toxicity, 16.7% of patients defaulted, 16.7% had virological failure and a further 14.6% had 
HAART modified due to other reasons.  
 
The factors associated with HAART modification are shown in Table 3 below. P < 0.1 in 
univariate analysis was considered significant. Patients with abnormal LFTs at the initiation 
of HAART were more likely to have their treatment modified (p = 0.01). Pregnant women on 
TAP were also more likely to have their HAART modified (p = 0.054). Other variables did 
not show significant association with modification of HAART. 
 
Table 3: Factors associated with modification of HAART – univariate analysis 
 
Characteristic  
Switched, N = 
48 
Not switched, 
N = 151 
P-value 
Age, median 
(IQR) 
Years 36.5 (32.5-40) 36 (30-41) 0.9209 
CD4, median 
(IQR) 
Cells/uL 252 (121-388) 180 (101-291) 0.952 
Weight, median 
(IQR) 
Kg 60 (50.7-76) 61 (53-73) 0.922 
Gender, n (%) 
Male 12 (19.4) 50 (80.7) 
0.290 
 
Female 36 (26.3) 101 (73.7) 
Lab findings, n 
(%) 
Abnormal LFT 4 (8.3) 6 (39.7) 0.010 
 
Abnormal RFT 5 (10.4) 3 (1.99) 0.228 
 
Abnormal Hb 12 (25) 42 (27.8) 0.702 
Comorbidities, n 
(%) 
TB 8 (16.7) 23 (15.2) 0.811 
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Cancer 3 (6.3) 16 (10.6) 0.372 
 
Anaemia 12 (25) 42 (27.8) 0.702 
 
Pregnancy 8 (16.7) 11 (7.3) 0.054 
 
Other 13 (27.1) 36 (23.8) 0.650 
WHO stage, n 
(%) 
1/2 21 (43.8) 67 (44.4) 
0.873 
 
3/4 27 (56.3) 84 (55.6) 
IQR = interquartile range, LFT = liver function test, RFT = renal function test, Hb = 
haemoglobin, TB= tuberculosis 
 
Factors with p-values less than 0.3 in the univariate analysis were entered into a multivariate 
logistic regression with switching (yes/no) as a binary outcome. After multivariate regression, 
only abnormal LFTs (odds ratio [OR] 11.86, 95% CI 1.18-119.20, p = 0.036) were associated 
with risk of switching. Pregnancy was also likely to be a risk factor although its OR did not 
reach statistical significance (OR 2.72, 95% CI 0.90-8.16, p = 0.075) (see Table 4 below). 
 
Table 4: Factors associated with modification of HAART – multivariate analysis 
 
Factor  AOR 
95% CI of 
AOR 
P-value 
Lab findings Abnormal LFT 11.86 1.18-119.2 0.036 
 TAP for pregnancy 2.72 0.90-8.16 0.075 
CI = confidence interval, AOR = adjusted odds ratio, LFT = liver function test, TAP = triple 
antiretroviral prophylaxis 
6. DISCUSSION 
The researcher observed a lower treatment modification rate of 0.09 per 100 person years 
within a median follow-up period of 6.9 months in this cohort. The reasons for modification 
were related to drug toxicity, virological failure, default and other. Having an abnormal LFT 
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at the initiation of HAART and being on TAP for pregnancy were significantly associated with 
increased risk of treatment modification. 
This rate of HAART modification was relatively lower compared to the rates found in studies 
done previously when the 2006 WHO guidelines were in use.[17, 18, 19] Studies with similar 
settings to compare to are limited. This lower rate of modification could be due to the high 
efficacy of the drugs used in this setting, facilitated by the improved 2010 WHO guidelines. 
Another contributing factor could be the use of TDF in the first-line regimen, which has been 
shown to cause a significant reduction in the risk of HAART modification.[11, 15, 20, 21] 
Because the PMH Infectious Disease Care Clinic (IDCC) is a referral unit with specialists, they 
may be assisting junior medical officers with decision making on HAART initiation. 
This rate is, however, still lower than that reported in some observational cohorts, mainly in 
North America and Europe where treatment modification rates are higher.[8, 22, 23, 24] There 
are several reasons that could have further attributed to the lower rates reported in this study. 
One of the reasons might be the lack of alternative treatment options in resource-limited 
settings such as Botswana. This shortcoming may inadvertently influence medical practitioners 
to be more hesitant to modify regimens.[14] Another reason could be that the current policies 
for treatment in resource-limited settings support the use of rigid predetermined cost-effective 
regimens.[15] Patients in resource-rich settings are more likely to be better informed about 
their care and would therefore foresee any unusual effects that could be attributed to their 
treatment. Better informed patients would be more likely to report any intolerance and have 
their drugs modified.  
Drug side effects or drug toxicities were the commonest reason for HAART modification, 
similar to what has been reported in other studies.[7, 14, 17, 25, 26] EFV and DT4 accounted 
for most drug toxicities – 20.9% and 18.8% respectively. A higher probability of treatment 
modification for adverse events has been observed with EFV.[25] Despite the fact that EFV 
has demonstrated high virological efficacy, neuropsychiatric and neurocognitive toxicity 
associated with this drug is not negligible.[27, 28] Both EFV- and NVP-toxicity-related 
modifications are higher in the first year post HAART initiation.[11] These observations should 
be taken into account when prescribing first-line HAART. Close clinical monitoring is 
warranted in EFV-treated patients. These findings also support the 2016 Botswana guidelines 
that recommend that EFV should be phased out and that DTG, which has a better tolerability, 
should be adopted.  
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Virological failure accounted for 16.7% of modifications, which may suggest drug resistance 
or low efficacy of first-line HAART in this region. This level of virological failure may also 
mean that there is an adequate and a proper mechanism in place to identify virological failure 
in this setting.   
Treatment default also accounted for 16.7% of modifications. These included patients who 
discontinued their treatment for their own reasons but who were restarted on treatment. A 
systematic review of patients who initiated HAART across sub-Saharan Africa found that 
approximately 25% had defaulted at 1 year after initiation, a figure rising to 40% after 2 
years.[29] Various studies have identified transport costs, time needed for treatment, and 
logistical challenges as main barriers to treatment, whereas stigma and side effects to HAART 
were less influential.[30, 31, 32, 33] In order to preserve the first-line HAART regimen at 
PMH, we need to reduce the financial and time burden of HAART and to reduce logistical 
barriers, such as simplifying the referral and transfer process, employing patient advocates, and 
adopting extended and weekend clinic hours. 
An abnormal LFT at the initiation of HAART was found to be a risk factor for treatment 
modification in this study. Various studies have reported a high prevalence of abnormal liver 
enzymes in HAART-naive patients.[34, 35, 36] This abnormality could be due to direct 
inflammation of hepatocytes by HIV through apoptosis or mitochondrial dysfunction and 
many more.[34] The underlying cause should always be investigated and properly managed 
prior to initiation of HAART since HAART has also been associated with drug-induced liver 
enzyme abnormalities.[34] In this study,  LFTs had not been recorded at the time of HAART 
modification, making it difficult to know whether these liver enzyme abnormalities directly 
caused modification of HAART. This could mean that even though liver enzymes were 
elevated at the beginning, the underlying pathology was identified and treated accordingly 
through the help of specialists in the hospital. However, just as the 2010 WHO guidelines 
recommend, monitoring and management of elevated liver enzymes prior to treatment should 
be reinforced in this setting.  
 
TAP during pregnancy was also found to be a risk factor for modification of HAART in 
univariate analysis (p = 0.054), but in multivariate analysis, the OR did not reach statistical 
significance. This is because the guidelines recommend cessation of HAART if the mother is 
stable postpartum without pregnancy complications or has not developed WHO stages 3 or 4 
or CD4 < 350. 
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Even though age, gender, CD4 count, WHO stage, baseline weight and comorbidities have 
been identified as predictive factors for HAART modification in other studies, it was not the 
case in this study.[7, 14, 17, 25, 26] The reason could be that when the 2010 WHO guidelines 
were drawn up, these factors were taken into consideration and better recommendations were 
made. It could also be that high-potency drugs were used at the time of this study or that the 
small sample size did not allow for them to be identified. 
 
The findings of this study should be interpreted in the light of its limitations. The analysis of a 
single treatment site, even though it is the largest in the country, may only reflect treatment 
practices at that centre, which limits generalisation to other sites. The fact that HIV specialists 
help to run the IDCC may also mean HAART modification is different from that at other 
centres in the country. The reasons for modification of HAART were not classified 
prospectively but were assessed from the retrospective review of patients’ medical records. In 
some cases, this could have led to imprecise classification. To strengthen the study, the 
researcher combined reasons for modification that were unlikely to be independent from each 
other. The other weakness is that the PMH IDCC is part of a big hospital with a significant 
number of people initiated on HAART as inpatients and then discharged to be followed up at 
local clinics. Such patients had no medical records opened for them in the IDCC even though 
they were initiated there, which could account for the small sample size of this study. The other 
important limitation of this study is that it reflects prescribing practices relating to a two-year 
period (2012-2014), which is no longer common practice. However, contributing to the 
strength of this data and analysis is the fact that every episode of modification of HAART and 
the reason for modification were captured by one researcher, which minimised errors in 
collecting data from the medical records.  
The findings of this study have implications for the management of patients on antiretroviral 
treatment. The identification of drug toxicity as the main reason for HAART modification calls 
for timely and proactive management of toxicity in order to prevent poor treatment outcomes, 
including treatment failure and default. The identification of abnormal LFTs as an important 
risk factor for HAART modification indicates that intensive assessment of patients for 
underlying liver pathology must be done prior to initiation. The common practice in the study 
setting is for all baseline bloods to be done prior to initiation and then for abnormal ones to be 
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acted upon before initiation of HAART. However, this needs to be reinforced to avoid initiation 
of HAART in patients with an uninvestigated cause of abnormal liver function. 
Further follow-up of large cohorts of patients is required to determine the long-term adherence 
to and toxicities of HAART and, ultimately, the long-term clinical outcome of patients on 
HAART. 
7. CONCLUSION 
This study found lower rates of HAART modification at the PMH IDCC compared to most 
studies in which previous HAART guidelines were in use. There are however, limited 
comparable studies to determine whether indeed patients in this cohort perfomed differently. 
Drug toxicity was identified as the most common reason for HAART modification while 
abnormal LFTs at HAART initiation and being on TAP for pregnancy were identified as 
predictive factors for treatment modification. Proactive management of drug toxicity to 
prevent poor treatment outcomes and careful investigation of abnormal LFT’s prior to 
HAART initiation is likely to be beneficial in the prevention of HAART modification.  
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APPENDIX 
Data extraction checklist 
Patient demographics 
Age:                                                                                        Gender: 
Baseline weight: 
Comorbidities:  Tuberculosis        Epilepsy      Arthritis      COPD/lung disease  
  Diabetes       Psychiatric illnesses      Cardiac disease     Liver disease     Cancer    
Other  
If other, specify _______________________ 
Clinical stage: 
Date commenced on initial HAART regimen: 
Initial HAART regimen: 
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Clinical parameters 
Baseline CD4: 
Baseline LFTs: 
Baseline RFTs: 
Baseline Hb: 
Reasons for modification: 
 
Date of HAART modification:  
 
Adapted  
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